Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

NCT00577837 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal

Interventions

DRUG: risedronate
DRUG: risedronate
DRUG: risedronate
DRUG: experimental

Sponsor

Warner Chilcott

Collaborators

[object Object]